Genesis Therapeutics
Daniel Zeng is currently serving as an ML Research Engineer at Genesis Therapeutics, focusing on deep learning and generative models for drug discovery since July 2023. Previously, Zeng worked as a Graduate Researcher at Stanford Artificial Intelligence Laboratory from September 2021 to April 2023, where a publication was contributed to the ICML 2022 Beyond Bayes Reasoning Workshop. Experience as a Graduate Teaching Assistant for Stanford University's CS 330 course on Deep Multi-Task and Meta Learning occurred in late 2022. Research internships at Google and ICSI involved model distillation for healthcare vision models and unsupervised image classification, respectively. Zeng also gained software engineering experience through internships at Stripe and Microsoft, alongside undergraduate research roles in machine learning at UC Berkeley's AUTOLab. Educational qualifications include a Master's degree in Computer Science from Stanford University and a Bachelor's degree in the same field from the University of California, Berkeley.
Genesis Therapeutics
3 followers
Genesis Therapeutics is an innovative biotechnology company engaging its proprietary molecular AI technology to transform clinical outcomes for patients. The company was founded in 2019 out of Stanford University by Evan Feinberg Ph.D., co-founded by Ben Sklaroff, and backed by Vijay Pande, Ph.D. In addition, Peppi Prasit, Ph.D. leads the Scientific Advisory Board and Leonard Bell, M.D., serves as Chair of the Board of Directors. Its team of technology trailblazers and proven drug developers are driving the discovery and development of novel small molecule drugs to treat patients suffering with severe and debilitating diseases. The company expects to develop drug candidates both internally and selectively in partnership with biopharmaceutical companies.